Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6177728 | 0.91 | HTR1A (0.56) | HTR1AKMT2AMEN1DRD2TSHR | |
| Cyclohexane SCHEMBL6178387 | 0.91 | MEN1 (0.48) | HTR1AKMT2AMEN1MAPTDRD2 | |
| SCHEMBL7760241 | 0.83 | MEN1 (0.54) | HTR1AKMT2AMEN1DRD2CHRM4 | |
| Cyclohexane SCHEMBL6180435 | 0.81 | MEN1 (0.48) | HTR1AKMT2AMEN1DRD2CHRM4 | |
| SCHEMBL6180578 | 0.79 | MEN1 (0.50) | KMT2AMEN1DRD2TRPV6CHRM4 | |
| SCHEMBL6177540 | 0.78 | MEN1 (0.46) | HTR1AKMT2AMEN1MAPTDRD2 | |
| SCHEMBL7968949 | 0.78 | MEN1 (0.45) | HTR1AKMT2AMEN1DRD2TRPV6 | |
| SCHEMBL6178229 | 0.78 | MEN1 (0.55) | HTR1AKMT2AMEN1DRD2TRPV6 | |
| SCHEMBL6180581 | 0.76 | MEN1 (0.53) | KMT2AMEN1DRD2TRPV6CHRM4 | |
| SCHEMBL6176842 | 0.76 | DRD4 (0.63) | HTR1AKMT2AMEN1DRD2TRPV6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140830-B1 | ARYLPIPERIDINE AND ARYL-1,2,5,6-TETRAHYDROPYRIDINE AMIDE DERIVATIVES HAVING 5HT1A RECEPTOR ACTIVITY | WYETH CORP (US) | 2005-05-04 | — | — | EP | claimed |
| US-20020035263-A1 | Novel arylpiperidine and aryl-1,2,5,6-tetrahydropyridine amide derivatives | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-21 | — | — | US | claimed |
| US-6326381-B1 | PSYCHOLOGICAL DISORDERS; NERVOUS SYSTEM DISORDERS | AMERICAN HOME PRODUCTS CORPORATION | 2001-12-04 | — | — | US | claimed |
| EP-1140830-B1 | ARYLPIPERIDINE AND ARYL-1,2,5,6-TETRAHYDROPYRIDINE AMIDE DERIVATIVES HAVING 5HT1A RECEPTOR ACTIVITY | WYETH CORP (US) | 2005-05-04 | — | — | EP | disclosed |
| US-20020035263-A1 | Novel arylpiperidine and aryl-1,2,5,6-tetrahydropyridine amide derivatives | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035263-A1 | Novel arylpiperidine and aryl-1,2,5,6-tetrahydropyridine amide derivatives | ADRA1D, ADH1C, HTR1D | HTR1A 11/4885KMT2A 945/4885MEN1 2956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.